Novel high-affinity salicylic acid-binding protein
CA 2268964 A1 · Owner: Rutgers, The State University Of New Jersey · Inventors: Klessig, Daniel F.; Du, He
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A high-affinity salicylic acid-binding protein (SABP2) derivable from tobacco and Arabidopsis is disclosed. The tobacco protein has a molecular weight of approximately 25 kDa and reversibly binds SA with an apparent Kd of approximately 90 nM and a Bmax of 10 fmol/mg protein. The SABP2 of the invention may be used to identify analogues of SA. Analogues so identified may be used in plants to augment disease-resistance response pathways or other SAsensitive processes in which SA plays a role. Possible examples include flowering and alternative respiration. The SABP2 of the invention may also be used to identify and clone a gene or cDNA that encodes it which then may be , used to …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 24, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 24, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 24, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.